GlassScriptPhysician profile
Liza Jane Plafsky
NPI 1356845325
$2,071.26
in general payments reported to CMS, 2019-2025
20 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $121 · 2023: $467 · 2024: $186 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.13 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $274.31 | 2023 | |
| Genzyme Corporation | $257.94 | 2025 | |
| Madrigal Pharmaceuticals | $234.13 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $222.57 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $173.41 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.13 | 2022 | |
| Medtronic, INC. | $110.20 | 2023 | Endoflip |
| Ardelyx, INC. | $108.41 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $105.07 | 2024-2025 | Dupixent |
| Abbvie INC. | $82.48 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.61 | 2024-2025 | Entyvio |
| Conmed Corporation | $57.60 | 2025 | Conmed Dilation, Conmed Hemostasis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.56 | 2025 | Xifaxan |
| Novo Nordisk INC | $43.01 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $39.79 | 2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $37.05 | 2025 | Capsocam Plus |
| Celltrion USA INC. | $35.38 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $30.35 | 2024-2025 | Suflave, Sutab |
| Evoke Pharma, INC. | $15.62 | 2025 | |
| Qol Medical, LLC | $13.64 | 2025 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liza Plafsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.